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ABSTRACT
Multidrug resistance (MDR) is a serious handicap towards the effective treatment of breast
cancer patients. One of the most prevalent MDR mechanisms is through the overexpression
of genes coding the proteins called Multidrug Resistance-associated Proteins (MRPs). The aim
of this study was to investigate the expression of MRP1 in tumor tissues from breast cancer
patients. In this study, a semi-quantitative RT-PCR approach was utilized. Our results suggest
that MRP1 overexpression can mediate MDR in patients. Pre-evaluation of the level of such MDR
mediators before chemotherapy can increase the efficacy of the treatment.
INTRODUCTION
Breast cancer is the most common cancer among women.
Combination of surgery, chemotherapy and radiation is used for
treatment of breast cancer. However, chemotherapy is mostly
rendered uneffective by multidrug resistance (MDR) mecha-
nisms towards a variety of chemotherapeutic agents. Increased
drug efflux is a common mechanism of resistance in cancer cells,
which is frequently seen following exposure of tumor cells to one
of the “naturally occurring” anticancer drugs like doxorubicin,
vincristine, etoposide, paclitaxel etc. (1). The increased drug ef-
flux is mediated by membrane transporter proteins. These mem-
brane proteins are physiological pumps that remove unwanted
chemicals. MDR1 is the most commonly used membrane pump
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that is involved in conferring resistance to cancer chemother-
apy (1). A second family of such pumps has gained attention
due to their ability to modulate drug resistance, the multidrug
resistance-associated proteins (MRPs). The first MRP protein
was reported in 1992 by Cole et al. (2). MRP1 is the first mem-
ber of the MRP family since many more have been identified
in recent years (3). They have been shown to confer resistance
when expressed in sensitive cells (4). Studies showed that MRP1
confers resistance to many chemotherapeutic drugs in many dif-
ferent cancers (4). MRP1 can transport uncharged hydrophobic
molecules, lipid soluble anions, and hydrophilic anions, includ-
ing glutathione (GSH) conjugates with multiple and fully dis-
sociating negative charges (5). However, although not essential,
GSH provides a modular effect on MRP1. For instance, in the
case of doxorubicin, it was shown that conjugation with GSH is
not the resistance mechanism in breast cancer cells (6). MRP1 is
basally expressed in almost all tissues tested (7). When MRP1
is overexpressed it has the ability to confer resistance to cy-
totoxic drugs like doxorubicin, vincristine and VP-16 (8). The
mechanisms by which MRP mediated MDR can develop could
be either intrinsic or acquired after chemotherapy. In this study,
MRP1gene expression was determined in various breast cancer
tissues from patients. Since overexpression of MRP1 may be
responsible for the failure of chemotherapy, the expression lev-
els were quantified and compared to that of controls, which can
provide clinicians with a useful tool to assess drug resistance
before treatment.
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MATERIALS AND METHODS
Cell lines and tissues
Fresh tissue samples (n=12) from patients (n=10) were pro-
vided by Demetevler Oncology Hospital (Ankara) and stored in
RNAlater (Ambion). Formalin fixed paraffin embedded (FFPE)
tissues (n = 2) by Gulhane Military Medical Academy, De-
partment of Pathology (Ankara). This study was conducted
according to Helsinki Declaration. HL60 cell line was ini-
tially provided by Gulhane Military Medical Academy, Depart-
ment of Hematology (Ankara) and subculturing was performed
in RPMI-1640 medium with 10% FCS. Doxorubicin resistant
HL60 subline was derived from parental HL60 cells by subcul-
turing in increasing doxorubicin concentrations up to 70 nM.
Doxorubicin sensitive and resistant HL60 cell lines were used
as negative and positive controls, respectively.
RNA isolation and cDNA preparation
Total RNA was isolated from both the tissues and the cell
lines as described previously (9). One to two milligrams of total
RNA was reverse transcribed to cDNA using Moloney Murine
Leukemia Virus Reverse Transcriptase (Moloney MLV, Fermen-
tas, Maryland, USA) according to the manufacturer’s protocol.
After 1 hr incubation at 42◦C, the reactions were stopped by
70◦C heating for 10 min.
Primers for PCR
MRP1 (10) and β-2-microglobulin (β2M) primers (11)
were obtained from IDT Technologies, (Iowa, USA). β2M
gene was used as an internal positive control (12). For nested
PCR, a second pair of MRP1 primers was designed. The
primer sequences were as follows: original MRP1-forward (5′-
GACCTGGACTTC GTTCTCA-3′), original MRP1-reverse (5′-
ACGTCCAGATTCCTT CATCC-3′, 291 bp); nested MRP1-
forward (5′-GACGGGAGCTGGGAAGTCGT-3′), nested
MRP1-reverse (5′-GGGAACCCGAAAACAAAACAG-3′, 115
bp) and β2M-forward (5′-ACCC CCACTGAAAAAGATGA-
3′), β2M-reverse (5′-ATCTTCAAACCTCCATGATG-3′, 166
bp).
Figure 1. Nested PCR amplification. A) First round of RT-PCR with MRP1 and β2M primers from poor quality RNA. Expected size of MRP1
primer product is 291 bp and β2M is 120 bp. B) The PCR products from panel A was used as a template for a second round of PCR with the
nested MRP1 primers. Expected size of nested MRP1 primer product is 166 bp.
Multiplex PCR
Multiplex PCR was performed for MRP1 and β2M primers.
For the nested multiplex PCR, the amplification product from
the initial PCR reaction was used. The program used for both of
the PCR reactions was as: initial denaturation at 94◦C for 30 sec;
denaturation at 94◦C for 30 sec, annealing at 60◦C for 30 sec,
extension at 72◦C for 45 sec with 30 cycles and final extension
at 72◦C for 5 min.
Densitometric analysis of PCR results
The gel images were processed with the Scion Image Soft-
ware (Scion Corporation, Maryland, USA). For the patients, the
calculated values of MRP1 band intensity of each sample was
divided to the β2M band intensity of the same sample. The ratio
of these intensities was called Ratio(P). The same ratio was ob-
tained for the sensitive [Ratio(S)] and resistant [Ratio(R)] HL60
cell lines by dividing the band intensity of MRP1 to the band in-
tensity of β2M. Then, the Ratio(P) was divided by the Ratio(S)
control [Ratio(P)/Ratio(S)] and Ratio(R) control was divided
by the Ratio(S) [Ratio(R)/Ratio(S)]. These standardized ratios
were used for determination of MRP1 overexpression relative
to a low MRP1 expressing control (sensitive HL60) and a high
MRP1 expressing cell line (resistant HL60) (13).
RESULTS
Expression analyses of MRP1 and β2M genes
in breast cancer patient samples
The ability of the nested MRP1 primers in amplification was
tested since a nested RT-PCR approach is more powerful for the
identification of degraded RNA in samples. In the first round of
the PCR reaction, cDNA preparations from FFPE tissues were
amplified with the original MRP1 primers amplifying a 291 bp
fragment (Fig. 1A). In most of the samples, the MRP1 band was
too weak to be visualized easily on an agarose gel (Fig. 1A).
A second round of PCR amplification was carried out using the
nested MRP1 primers, which amplify an internal fragment of
166 bp (Fig. 1B). After the optimization studies RT-PCR was
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Figure 2. Multiplex PCR results of patient samples. (A) Semi-quantitative multiplex RT-PCR analysis for MRP1 and β2M gene expressions in 6
patient samples (P1A, P2A, P2B, P4 and P5). Sample P1B failed to give detectable PCR product. HL60-S (sensitive) and HL60-R (resistant) cell
lines were used for comparison as described in the text. The first lane was the DNA size marker. Expected size of nested MRP1 primer product
is 166 bp and β2M is 120 bp. (B) Semi-quantitative multiplex RT-PCR analysis for MRP1 and β2M gene expressions in 6 patient samples (P3,
P6, P7, P8, P9 and P10). Samples P3, P6, P7 and P8 failed to give detectable PCR product. Expected size of nested MRP1 primer product is
166 bp and β2M is 120 bp.
performed for all patient samples by using either the nested
MRP1 primers or the original MRP1 primers. Sensitive (S) and
resistant (R) HL60 cells were used as controls. The agarose
gel images of multiplex PCR products (MRP1 and β2M) from
samples are shown in Figs. 2 and 3. The multiplex PCR in Fig. 3B
was performed using only the MRP1 primers (291 bp) without
the use of nested PCR. Samples P1B, P7 and P8 were excluded
since the samples failed to give any detectable PCR products
(neither with MRP1 nor β2M). It is possible that the samples
were not stored adequately therefore no RNA was preserved.
Figure 3. Multiplex PCR results of patient samples. (A) Semi-quantitative multiplex RT-PCR analysis for MRP1 and β2M gene expressions in 2
formalin-fixed paraffin embedded patient tissue samples (P11, P12). HL60-S and HL60-R cell lines were used for comparison as described in the
text. The first lane was the DNA size marker. Expected size of nested MRP1 primer product is 166 bp and β2M is 120 bp. (B) Semi-quantitative
multiplex RT-PCR analysis for MRP1 and β2M gene expressions in 5 patient samples (P1A, P3, P2B, P2A and P6). Expected size of MRP1
primer product is 291 bp and β2M is 120 bp.
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Table 1. Densitometry analysis of the RT-PCR results.
Code A260 A280 Purity mg/ml
P1A 0.23 0.141 1.63 0.920
P1B 0.63 0.329 1.91 2.520
P2A 0.3 0.175 1.71 1.200
P2B 0.246 0.172 1.43 0.984
P3 0.285 0.153 1.86 1.140
P4 0.678 0.367 1.85 2.712
P5 1.235 0.783 1.58 4.940
P6 0.096 0.074 1.30 0.384
P7 0.102 0.08 1.28 0.408
P8 0.117 0.078 1.50 0.468
P9 0.268 0.156 1.72 1.072
P10 0.5 0.273 1.83 2.000
P11 FFPE from Gulhane
P12 FFPE from Gulhane
Ratio (P) = Ratio of the Patient; Ratio (S) = Ratio of the sensitive
HL60 control; Ratio (R) = Ratio of the Resistant HL60 control.
Densitometric analysis
Densitometric analysis of the bands obtained after gel
electrophoresis were done as described in the Materials and
Methods. The gel images given in Figs. 2 and 3 were quantified
using densitometry software in order to determine the band
intensities. These values were first standardized against the
β2M intensities by simply dividing the values of the MRP1 band
intensities of the patient samples to β2M band intensities of the
same sample. Then these ratios were re-standardized by dividing
to the ratio of the HL60 sensitive control, which has a basal level
MRP1 expression (14). The results of these analyses are given in
Table 1.
The important values in Table 1 are the Ratio (P)/Ratio (S),
which is the sensitive HL60 standardized ratio of the patient,
and the Ratio (R)/Ratio (S), which is the sensitive HL60 stan-
dardized ratio of the resistant HL60 control. Such standard-
ization was used in order to reduce experiment-to-experiment
variability between samples and gels. Densitometry analyses
indicated in Table 1 were used for deciding whether patients
displayed overexpression or not. If the patient sample displayed
a Ratio(P)/Ratio(S) value lower than 1, it was considered as
“basal expression.” However, if the Ratio(P)/Ratio(S) value was
higher than 1, then it was an “overexpression” case. A third
category was assigned for the samples that have a higher Ra-
tio(P)/Ratio(S) value than the Ratio(R)/Ratio(S) value, which in
this case considered as “high overexpression.”
A final decision was made by comparing these values. The
value of the patient was compared with that of the controls’
value within the same agarose gel. The mean value of the Ratio
(R)/Ratio (S) was found to be 1.24 with a standard deviation of
0.12.
DISCUSSION
Before densitometry analysis, the samples must be loaded
together with the control onto the gels. There were two controls
to limit experiment-to-experiment variations. First control is
the β2M, which is definitely necessary to eliminate sample-
to-sample variations. However, this is still not enough, since
samples are run on different gels or the PCR was performed
on different days in most cases. Thus, we need a second
control, which is HL60(S), to overcome the gel-to-gel varia-
tions. Third and last, HL60(R) was included for comparison of
overexpression.
All patients received anthracycline based chemotherapy pro-
tocols. The patients P1A, P5, P6, P10, P11 and P12 expressed
much higher MRP1 than the doxorubicin resistant HL60 cell
line. So, these patients may not respond to chemotherapy as
expected. Clinical results after administration of chemothera-
peutic agents showed that for P1 the size of the tumor size only
reduced 12.5%, which is considered to be not very significant.
Interestingly, P2 showed an increase in resistance about 25%
after the application of chemotherapy. While P2, P9 and P10
died, and for all the other patients, the chemotherapy is still con-
tinuing and a second tissue sample after chemotherapy was not
available. Therefore, a definitive conclusion cannot be made.
However, here it can be concluded that P1 has an intrinsic re-
sistance, while P2 has gained a higher degree of resistance after
chemotherapy. Initially, P2A can be considered as basal level
expression since the Ratio(P)/Ratio (S) was 1.02, but the second
sample (P2B) from the same patient definitely has an overex-
pression, which implies the occurrence of an acquired type of
resistance. For P4, it is interesting to see the β2M band only. It
can be concluded that either the patient has a very low level of
expression most probably below the detection limit or there is
no expression at all.
In this study we demonstrated that multidrug resistance me-
diated by MRP1 overexpression could be a determinant factor in
multidrug resistance in breast cancer. The therapeutic outcome
was correlated with the expression of MRP1, so the precise de-
termination of the levels of MRP1 expression is very important.
This work is important in the sense that a protocol for the quanti-
tative determination of one of the multidrug transporters, MRP1,
was optimized not only from fresh tissue samples, but also from
FFPE tissues. It is difficult to get well-conserved fresh samples
for expression analyses since tissues should be preserved fresh
after removal. Also doctors are not willing to spare tumor tissue
since a thorough pathology report needs to be done. Therefore,
it is not easy to get surgeons cooperate in such studies. How-
ever, it is very easy to find FFPE tissue for both retrospective
and prospective studies. In this manner, this study is valuable
especially when there are not many studies in Turkish litera-
ture using such approaches described in this work for predicting
chemotherapeutic outcome mediated by MDR.
Overexpression of MRP1 results in resistance to different
types of anticancer agents used for the treatment of breast can-
cer patients currently (15–16). It was strongly suggested that
expression of MRP1 gene is responsible for a negative response
in early breast cancer and thus MRP1 gene expression levels can
be used as marker for breast cancer (17). Leonessa et al. have
shown that early expression of MRP1 is directly correlated with a
worse prognosis (18) while Trock et al. demonstrated that MRP1
204 O. D. Abaan et al.
gene expression was in low levels before chemotherapy in breast
cancer samples as compared to the samples after chemotherapy
(19).
Similar studies also aid the determination of the drug trans-
porters involved in MDR in cancer patients and their correlation
with and/or prediction of outcome in the clinic. In the future,
with the characterization of these MDR transporters, person-
alized treatment strategies could be developed to increase the
chemotherapeutic efficacy.
ABBREVIATIONS
FFPE = Formalin fixed parafin embedded
GSH = glutathione
MDR = Multidrug resistance
MRP1 = Multidrug Resistance-associated Protein-1
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